Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
BörsenkürzelDNA
Name des UnternehmensGinkgo Bioworks Holdings Inc
IPO-datumApr 19, 2021
CEODr. Jason Kelly
Anzahl der mitarbeiter834
WertpapierartOrdinary Share
GeschäftsjahresendeApr 19
Addresse27 Drydock Avenue
StadtBOSTON
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl02210
Telefon18774425362
Websitehttps://investors.ginkgobioworks.com/
BörsenkürzelDNA
IPO-datumApr 19, 2021
CEODr. Jason Kelly
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten